Replies to post #3506 on Diffusion Pharmaceuticals Inc (DFFN)

[glens0]

Based on our probability adjusted DCF model that
takes into account potential future revenues from TSC
in select hypoxia-related indications, DFFN is valued at
$2.00/share. This model is highly dependent upon the
continued clinical success of TSC and will be adjusted
accordingly based upon future clinical results.